TABLE 2.

Progression-free survival, overall survival, and disease control rates by histology and EGFR and HER2 expression

	ACC (N=18)	Non-ACC (N=18)
Median progression-free survival (95% CI)
All	4.4 mo (2.2–11.7 mo)	2.1 mo (1.7–5.6 mo)
EGFR-positive	6.0 mo (3.5-NR mo)	2.1 mo (1.1-NR mo)
EGFR-negative	4.3 mo (1.8-NR mo)	2.1 mo (1.7-NR mo)
HER2-positive		2.0 mo (1.6-NR mo)
HER2-negative	5.1 mo (2.2–13.9 mo)	2.1 mo (1.9-NR mo)
Median overall survival (95% CI)
All	25.9 (13.9, 57.8) (n=18)	16.0 mo (7.6–44.6 mo)
EGFR-positive	18.6 (10.5, NR) (n=6)	30.8 mo (3.4-NR mo)
EGFR-negative	37.2 (25.9, NR) (n=10)	14.9 mo (7.6-NR mo)
HER2-positive		17.2 mo (5.2-NR mo)
HER2-negative	28.1 (22.0, 59.5) (n=16)	12.2 mo (7.6-NR mo)
Disease control rates *
All	14/17(82% )	6/17(35%)
EGFR-positive	5/5(100%)	1/3(33%)
EGFR-negative	8/10 (80%)	5/13(38%)
HER2-positive		3/9(33%)
HER2-negative	13/15(87%)	3/8(38%)

^*Estimated from patients evaluable for response.

ACC: adenoid cystic carcinoma; non ACC: non-adenoid cystic carcinoma; NR: Not reached.